Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorouracil | 57 | 2022 | 1642 | 2.630 |
Why?
|
Colonic Neoplasms | 60 | 2022 | 2527 | 2.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 93 | 2022 | 11733 | 2.350 |
Why?
|
Colorectal Neoplasms | 52 | 2022 | 6919 | 2.010 |
Why?
|
Organoplatinum Compounds | 12 | 2016 | 407 | 1.420 |
Why?
|
Leucovorin | 29 | 2022 | 643 | 1.400 |
Why?
|
Adenocarcinoma | 45 | 2019 | 6341 | 1.370 |
Why?
|
Gastrointestinal Neoplasms | 17 | 2023 | 955 | 1.340 |
Why?
|
Rectal Neoplasms | 32 | 2022 | 1156 | 1.330 |
Why?
|
Deoxycytidine | 12 | 2010 | 878 | 1.320 |
Why?
|
Trifluridine | 2 | 2018 | 28 | 1.120 |
Why?
|
Anus Neoplasms | 11 | 2024 | 330 | 1.080 |
Why?
|
Camptothecin | 17 | 2022 | 591 | 1.000 |
Why?
|
Medical Oncology | 16 | 2023 | 2320 | 0.980 |
Why?
|
Cystitis, Interstitial | 7 | 2012 | 66 | 0.890 |
Why?
|
Leukemia, Myeloid | 17 | 2006 | 693 | 0.890 |
Why?
|
Antimetabolites, Antineoplastic | 16 | 2010 | 646 | 0.870 |
Why?
|
Cytarabine | 23 | 2008 | 697 | 0.760 |
Why?
|
Neoplasm Recurrence, Local | 37 | 2019 | 9278 | 0.670 |
Why?
|
Esophagogastric Junction | 3 | 2017 | 347 | 0.660 |
Why?
|
Cisplatin | 15 | 2017 | 1652 | 0.650 |
Why?
|
Neoplasm Staging | 52 | 2019 | 11119 | 0.630 |
Why?
|
Chemotherapy, Adjuvant | 41 | 2018 | 3512 | 0.630 |
Why?
|
Uracil | 3 | 2018 | 207 | 0.630 |
Why?
|
Antineoplastic Agents | 33 | 2016 | 13632 | 0.620 |
Why?
|
Stomach Neoplasms | 11 | 2017 | 1457 | 0.550 |
Why?
|
Esophageal Neoplasms | 10 | 2016 | 1658 | 0.520 |
Why?
|
Pancreatic Neoplasms | 15 | 2018 | 5366 | 0.500 |
Why?
|
Withholding Treatment | 1 | 2018 | 616 | 0.460 |
Why?
|
Liver Neoplasms | 15 | 2012 | 4309 | 0.440 |
Why?
|
Combined Modality Therapy | 35 | 2017 | 8519 | 0.440 |
Why?
|
Disease-Free Survival | 34 | 2017 | 6819 | 0.420 |
Why?
|
Leukemia | 14 | 2022 | 1518 | 0.410 |
Why?
|
Carcinoembryonic Antigen | 12 | 2007 | 335 | 0.400 |
Why?
|
Societies, Medical | 8 | 2018 | 3923 | 0.390 |
Why?
|
Neoplasm Metastasis | 21 | 2019 | 4909 | 0.390 |
Why?
|
Infusions, Intravenous | 17 | 2009 | 2217 | 0.380 |
Why?
|
Survival Analysis | 35 | 2015 | 10088 | 0.380 |
Why?
|
BCG Vaccine | 4 | 2007 | 369 | 0.380 |
Why?
|
Drug Administration Schedule | 24 | 2018 | 4851 | 0.360 |
Why?
|
Neoadjuvant Therapy | 4 | 2008 | 2827 | 0.360 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2024 | 4021 | 0.350 |
Why?
|
Leukemia, Myeloid, Acute | 28 | 2008 | 3609 | 0.350 |
Why?
|
Middle Aged | 157 | 2022 | 220853 | 0.340 |
Why?
|
Aged | 127 | 2022 | 169288 | 0.340 |
Why?
|
Treatment Outcome | 55 | 2022 | 64681 | 0.340 |
Why?
|
Humans | 274 | 2024 | 761208 | 0.330 |
Why?
|
Survival Rate | 26 | 2019 | 12728 | 0.330 |
Why?
|
Antibodies, Monoclonal | 14 | 2016 | 9187 | 0.330 |
Why?
|
Dietary Sucrose | 3 | 2018 | 243 | 0.320 |
Why?
|
Colonography, Computed Tomographic | 1 | 2010 | 170 | 0.310 |
Why?
|
Radiotherapy, Adjuvant | 11 | 2007 | 1784 | 0.310 |
Why?
|
Biliary Tract Neoplasms | 1 | 2010 | 185 | 0.300 |
Why?
|
Prodrugs | 3 | 2008 | 262 | 0.290 |
Why?
|
Thymine | 2 | 2018 | 68 | 0.280 |
Why?
|
Glycolipids | 1 | 2007 | 206 | 0.280 |
Why?
|
Female | 173 | 2019 | 392544 | 0.280 |
Why?
|
Adult | 140 | 2022 | 221119 | 0.270 |
Why?
|
Male | 157 | 2019 | 360693 | 0.270 |
Why?
|
Remission Induction | 20 | 2008 | 2392 | 0.260 |
Why?
|
Cystoscopy | 1 | 2006 | 131 | 0.260 |
Why?
|
Colostomy | 4 | 2013 | 105 | 0.260 |
Why?
|
Intestinal Neoplasms | 1 | 2008 | 315 | 0.250 |
Why?
|
Research Support as Topic | 1 | 2010 | 697 | 0.250 |
Why?
|
Aged, 80 and over | 50 | 2019 | 58952 | 0.250 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2018 | 1726 | 0.250 |
Why?
|
Pyrrolidines | 2 | 2018 | 339 | 0.240 |
Why?
|
Hepatectomy | 2 | 2007 | 557 | 0.240 |
Why?
|
Esophagectomy | 2 | 2008 | 469 | 0.240 |
Why?
|
Chromosome Aberrations | 9 | 2006 | 1767 | 0.230 |
Why?
|
Sweetening Agents | 2 | 2018 | 290 | 0.220 |
Why?
|
Euthanasia | 2 | 2001 | 58 | 0.220 |
Why?
|
Lymphatic Metastasis | 11 | 2010 | 2913 | 0.220 |
Why?
|
Suicide, Assisted | 2 | 2001 | 68 | 0.220 |
Why?
|
Mass Screening | 5 | 2018 | 5426 | 0.220 |
Why?
|
Daunorubicin | 12 | 2008 | 157 | 0.210 |
Why?
|
Proportional Hazards Models | 21 | 2018 | 12474 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 10 | 2018 | 6486 | 0.210 |
Why?
|
Mitomycin | 5 | 2013 | 263 | 0.210 |
Why?
|
Prognosis | 43 | 2019 | 29687 | 0.210 |
Why?
|
Microsatellite Instability | 6 | 2013 | 716 | 0.210 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2017 | 380 | 0.200 |
Why?
|
Taxoids | 5 | 2009 | 668 | 0.200 |
Why?
|
Intestine, Small | 1 | 2008 | 1207 | 0.200 |
Why?
|
Levamisole | 6 | 2006 | 35 | 0.190 |
Why?
|
Carcinoid Tumor | 2 | 2004 | 225 | 0.190 |
Why?
|
Chromosomes, Human, Pair 8 | 7 | 2004 | 452 | 0.190 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 4014 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 11 | 2018 | 10756 | 0.190 |
Why?
|
Angiogenesis Inhibitors | 2 | 2008 | 2047 | 0.180 |
Why?
|
Euthanasia, Active, Voluntary | 1 | 2000 | 12 | 0.180 |
Why?
|
Drug Combinations | 3 | 2018 | 2048 | 0.180 |
Why?
|
Immunotherapy | 3 | 2007 | 4642 | 0.180 |
Why?
|
Epirubicin | 2 | 2017 | 81 | 0.180 |
Why?
|
Anemia, Hemolytic | 2 | 2001 | 163 | 0.180 |
Why?
|
Adjuvants, Immunologic | 4 | 2007 | 988 | 0.180 |
Why?
|
Microsatellite Repeats | 5 | 2009 | 782 | 0.170 |
Why?
|
Early Detection of Cancer | 4 | 2018 | 3198 | 0.170 |
Why?
|
Cancer Vaccines | 1 | 2007 | 1038 | 0.170 |
Why?
|
Glycoproteins | 1 | 2007 | 2203 | 0.170 |
Why?
|
Loss of Heterozygosity | 5 | 2011 | 662 | 0.170 |
Why?
|
Prospective Studies | 36 | 2024 | 54435 | 0.170 |
Why?
|
Anal Canal | 3 | 2004 | 374 | 0.170 |
Why?
|
Vitamins | 3 | 2019 | 1634 | 0.170 |
Why?
|
Lymph Node Excision | 3 | 2003 | 1270 | 0.160 |
Why?
|
History, 20th Century | 4 | 2014 | 2765 | 0.160 |
Why?
|
Acute Disease | 21 | 2006 | 7226 | 0.160 |
Why?
|
Exercise | 4 | 2019 | 5874 | 0.160 |
Why?
|
Interprofessional Relations | 3 | 2012 | 990 | 0.160 |
Why?
|
Injections, Intravenous | 4 | 2006 | 1376 | 0.160 |
Why?
|
Genes, ras | 3 | 2009 | 654 | 0.160 |
Why?
|
Organizational Culture | 2 | 2012 | 509 | 0.150 |
Why?
|
Bone Marrow Transplantation | 7 | 1993 | 2692 | 0.150 |
Why?
|
Digestive System Surgical Procedures | 5 | 2011 | 571 | 0.150 |
Why?
|
Clinical Trials as Topic | 19 | 2007 | 8003 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2000 | 420 | 0.150 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2002 | 328 | 0.140 |
Why?
|
Biomedical Research | 3 | 2010 | 3434 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 1998 | 1549 | 0.140 |
Why?
|
Diarrhea | 4 | 2006 | 1316 | 0.140 |
Why?
|
Follow-Up Studies | 28 | 2019 | 39126 | 0.140 |
Why?
|
Chromosomes, Human, Pair 21 | 4 | 2004 | 227 | 0.140 |
Why?
|
Drug Evaluation | 12 | 1993 | 641 | 0.140 |
Why?
|
Treatment Failure | 8 | 2016 | 2643 | 0.140 |
Why?
|
Cyclooxygenase 2 | 1 | 2019 | 597 | 0.130 |
Why?
|
Outpatient Clinics, Hospital | 1 | 1998 | 392 | 0.130 |
Why?
|
Neoplasms | 19 | 2016 | 22140 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 14 | 2019 | 10218 | 0.130 |
Why?
|
Continuity of Patient Care | 1 | 2003 | 1069 | 0.130 |
Why?
|
History, 21st Century | 2 | 2014 | 1567 | 0.130 |
Why?
|
Hyperinsulinism | 1 | 2019 | 400 | 0.130 |
Why?
|
Leukemia, Promyelocytic, Acute | 3 | 1997 | 249 | 0.130 |
Why?
|
Nuts | 1 | 2018 | 264 | 0.130 |
Why?
|
Endpoint Determination | 1 | 2018 | 590 | 0.130 |
Why?
|
Age Factors | 13 | 2018 | 18384 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 1998 | 422 | 0.130 |
Why?
|
Beverages | 2 | 2018 | 821 | 0.120 |
Why?
|
Translocation, Genetic | 8 | 2004 | 1391 | 0.120 |
Why?
|
Attitude of Health Personnel | 3 | 2012 | 3885 | 0.120 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1995 | 176 | 0.120 |
Why?
|
Maximum Tolerated Dose | 4 | 2013 | 883 | 0.120 |
Why?
|
Glutathione S-Transferase pi | 1 | 2015 | 99 | 0.120 |
Why?
|
Time Factors | 25 | 2018 | 39957 | 0.120 |
Why?
|
United States | 22 | 2019 | 72339 | 0.120 |
Why?
|
Leukemia, Lymphoid | 6 | 1986 | 311 | 0.120 |
Why?
|
Radiology Department, Hospital | 1 | 1998 | 407 | 0.120 |
Why?
|
Vitamin D | 2 | 2019 | 3301 | 0.120 |
Why?
|
Diet | 4 | 2019 | 8048 | 0.120 |
Why?
|
Infusions, Intra-Arterial | 2 | 2006 | 221 | 0.120 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1616 | 0.120 |
Why?
|
Administration, Intravesical | 4 | 2007 | 91 | 0.120 |
Why?
|
DNA Methylation | 5 | 2006 | 4384 | 0.110 |
Why?
|
Risk Factors | 23 | 2019 | 74239 | 0.110 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1993 | 79 | 0.110 |
Why?
|
Karyotyping | 8 | 2004 | 1172 | 0.110 |
Why?
|
Neutropenia | 5 | 2006 | 885 | 0.110 |
Why?
|
Pyridines | 1 | 2005 | 2872 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2005 | 620 | 0.100 |
Why?
|
Chromosome Disorders | 2 | 1995 | 497 | 0.100 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2014 | 321 | 0.100 |
Why?
|
Social Dominance | 1 | 2012 | 39 | 0.100 |
Why?
|
Health Facility Administration | 1 | 2012 | 29 | 0.100 |
Why?
|
Mutation | 10 | 2019 | 30002 | 0.100 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2006 | 2421 | 0.100 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2006 | 219 | 0.100 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2014 | 371 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2023 | 610 | 0.090 |
Why?
|
Palliative Care | 5 | 2005 | 3599 | 0.090 |
Why?
|
Coffee | 1 | 2015 | 593 | 0.090 |
Why?
|
Central Nervous System Neoplasms | 4 | 2008 | 915 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2019 | 2054 | 0.090 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2011 | 247 | 0.090 |
Why?
|
Colonoscopy | 5 | 2018 | 1395 | 0.090 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2006 | 732 | 0.090 |
Why?
|
Trisomy | 4 | 2002 | 261 | 0.090 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2017 | 181 | 0.090 |
Why?
|
Desensitization, Immunologic | 1 | 2016 | 557 | 0.090 |
Why?
|
Neuroendocrine Tumors | 2 | 2013 | 642 | 0.090 |
Why?
|
Agranulocytosis | 3 | 2005 | 97 | 0.090 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9416 | 0.090 |
Why?
|
Glycemic Index | 1 | 2012 | 396 | 0.090 |
Why?
|
MutS Homolog 2 Protein | 3 | 2017 | 197 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2013 | 3493 | 0.090 |
Why?
|
Organizational Policy | 1 | 2012 | 431 | 0.080 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2009 | 68 | 0.080 |
Why?
|
Lymph Nodes | 3 | 2013 | 3461 | 0.080 |
Why?
|
ras Proteins | 2 | 2013 | 1055 | 0.080 |
Why?
|
Foundations | 1 | 2010 | 95 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 858 | 0.080 |
Why?
|
Carcinoma | 4 | 2006 | 2330 | 0.080 |
Why?
|
Pelvic Pain | 2 | 2009 | 298 | 0.080 |
Why?
|
Analysis of Variance | 5 | 2013 | 6223 | 0.080 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 1989 | 258 | 0.080 |
Why?
|
Double-Blind Method | 4 | 2015 | 12341 | 0.080 |
Why?
|
Quality of Life | 7 | 2012 | 13367 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 2270 | 0.080 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2002 | 410 | 0.080 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2004 | 386 | 0.080 |
Why?
|
Administration, Oral | 4 | 2007 | 4015 | 0.080 |
Why?
|
Diffusion of Innovation | 1 | 2014 | 730 | 0.080 |
Why?
|
Research Design | 2 | 2018 | 6180 | 0.080 |
Why?
|
Etoposide | 5 | 2005 | 635 | 0.080 |
Why?
|
Biopsy | 1 | 2001 | 6781 | 0.080 |
Why?
|
Terminal Care | 1 | 2001 | 1760 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2014 | 1334 | 0.080 |
Why?
|
Disease Progression | 8 | 2019 | 13511 | 0.080 |
Why?
|
Financing, Organized | 1 | 2010 | 204 | 0.080 |
Why?
|
Immunocompromised Host | 1 | 1993 | 858 | 0.080 |
Why?
|
Mitoxantrone | 4 | 2005 | 148 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 3 | 2013 | 4513 | 0.070 |
Why?
|
DNA, Neoplasm | 3 | 2018 | 1743 | 0.070 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2014 | 1318 | 0.070 |
Why?
|
Aziridines | 4 | 2005 | 21 | 0.070 |
Why?
|
Incidence | 8 | 2018 | 21365 | 0.070 |
Why?
|
Promoter Regions, Genetic | 5 | 2006 | 5773 | 0.070 |
Why?
|
Chromosome Inversion | 3 | 2004 | 119 | 0.070 |
Why?
|
Hepatic Artery | 2 | 2006 | 232 | 0.070 |
Why?
|
Drug Administration Routes | 1 | 2007 | 150 | 0.070 |
Why?
|
Aggression | 1 | 2012 | 748 | 0.070 |
Why?
|
Granulocytes | 3 | 1989 | 550 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2014 | 2897 | 0.070 |
Why?
|
Patient Care Team | 1 | 1998 | 2515 | 0.070 |
Why?
|
Economics, Medical | 1 | 2007 | 112 | 0.070 |
Why?
|
Models, Genetic | 1 | 2017 | 3430 | 0.070 |
Why?
|
Professional-Patient Relations | 1 | 2012 | 723 | 0.070 |
Why?
|
Drug Hypersensitivity | 1 | 2016 | 918 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1838 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2915 | 0.070 |
Why?
|
Recurrence | 13 | 2012 | 8457 | 0.070 |
Why?
|
Forecasting | 2 | 2014 | 2928 | 0.070 |
Why?
|
Benzoquinones | 4 | 2005 | 198 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5828 | 0.070 |
Why?
|
Lymphoma | 3 | 1993 | 1898 | 0.070 |
Why?
|
Adolescent | 34 | 2008 | 88298 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1327 | 0.070 |
Why?
|
Hospitals | 3 | 2012 | 3881 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2007 | 355 | 0.070 |
Why?
|
Ovarian Neoplasms | 2 | 2000 | 4872 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 2 | 1997 | 592 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2019 | 3089 | 0.070 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 694 | 0.060 |
Why?
|
Aminoacridines | 1 | 1985 | 9 | 0.060 |
Why?
|
Recreation | 1 | 2006 | 125 | 0.060 |
Why?
|
Social Behavior | 1 | 2012 | 1136 | 0.060 |
Why?
|
Chromosomal Instability | 1 | 2006 | 178 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2001 | 4320 | 0.060 |
Why?
|
Urinary Bladder Diseases | 1 | 2006 | 167 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2009 | 360 | 0.060 |
Why?
|
Awards and Prizes | 1 | 2010 | 362 | 0.060 |
Why?
|
Urodynamics | 1 | 2007 | 346 | 0.060 |
Why?
|
Sexuality | 1 | 2007 | 180 | 0.060 |
Why?
|
Doxorubicin | 9 | 2004 | 2224 | 0.060 |
Why?
|
Hodgkin Disease | 3 | 1998 | 1379 | 0.060 |
Why?
|
Placebos | 2 | 2010 | 1666 | 0.060 |
Why?
|
Germ-Line Mutation | 3 | 2018 | 1852 | 0.060 |
Why?
|
Cohort Studies | 12 | 2019 | 41496 | 0.060 |
Why?
|
Urogenital Neoplasms | 5 | 2008 | 131 | 0.060 |
Why?
|
Skin Neoplasms | 4 | 2006 | 5809 | 0.060 |
Why?
|
DNA-Binding Proteins | 5 | 2017 | 9566 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 1 | 2010 | 788 | 0.060 |
Why?
|
Sex Factors | 6 | 2014 | 10553 | 0.060 |
Why?
|
Insulin | 1 | 2019 | 6588 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2864 | 0.060 |
Why?
|
Splenomegaly | 1 | 2004 | 191 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2009 | 2928 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2058 | 0.060 |
Why?
|
Urination | 1 | 2005 | 203 | 0.060 |
Why?
|
Body Mass Index | 4 | 2012 | 12952 | 0.060 |
Why?
|
Floxuridine | 1 | 1983 | 44 | 0.060 |
Why?
|
Esophageal Fistula | 1 | 2003 | 60 | 0.050 |
Why?
|
Quinazolines | 2 | 2007 | 1371 | 0.050 |
Why?
|
Bone Marrow | 4 | 1995 | 2911 | 0.050 |
Why?
|
Vitamin B Complex | 1 | 2005 | 299 | 0.050 |
Why?
|
Physical Exertion | 1 | 2006 | 668 | 0.050 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1983 | 39 | 0.050 |
Why?
|
Radiotherapy Dosage | 3 | 2008 | 2897 | 0.050 |
Why?
|
Statistics, Nonparametric | 3 | 2008 | 2854 | 0.050 |
Why?
|
Anxiety Disorders | 2 | 2009 | 2723 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6567 | 0.050 |
Why?
|
Aspirin | 1 | 2014 | 3129 | 0.050 |
Why?
|
Transcription Factors | 4 | 2004 | 12099 | 0.050 |
Why?
|
Risk Assessment | 7 | 2017 | 24021 | 0.050 |
Why?
|
CA-19-9 Antigen | 2 | 2010 | 106 | 0.050 |
Why?
|
Occult Blood | 2 | 2018 | 197 | 0.050 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2004 | 343 | 0.050 |
Why?
|
Chromans | 1 | 2002 | 117 | 0.050 |
Why?
|
Gallbladder Neoplasms | 1 | 2004 | 189 | 0.050 |
Why?
|
Disabled Persons | 1 | 2012 | 1224 | 0.050 |
Why?
|
DNA Mismatch Repair | 3 | 2011 | 428 | 0.050 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2002 | 192 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 411 | 0.050 |
Why?
|
CpG Islands | 1 | 2006 | 1190 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8530 | 0.050 |
Why?
|
Immunity, Cellular | 1 | 2007 | 1553 | 0.050 |
Why?
|
Phosphonoacetic Acid | 1 | 2001 | 54 | 0.050 |
Why?
|
Canada | 2 | 2012 | 2125 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2012 | 7400 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 2 | 2017 | 2803 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1988 | 1372 | 0.040 |
Why?
|
Lung Neoplasms | 12 | 2008 | 13385 | 0.040 |
Why?
|
Safety | 1 | 2005 | 1151 | 0.040 |
Why?
|
Salvage Therapy | 2 | 2004 | 1264 | 0.040 |
Why?
|
Thrombocytopenia | 2 | 2006 | 1182 | 0.040 |
Why?
|
Thoracoscopy | 1 | 2001 | 183 | 0.040 |
Why?
|
Pregnancy | 5 | 2019 | 29893 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20588 | 0.040 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2001 | 173 | 0.040 |
Why?
|
Lymphocytes | 4 | 1991 | 2603 | 0.040 |
Why?
|
Hormone Replacement Therapy | 2 | 2007 | 751 | 0.040 |
Why?
|
Pain, Intractable | 1 | 2000 | 132 | 0.040 |
Why?
|
Carcinoid Heart Disease | 1 | 1999 | 10 | 0.040 |
Why?
|
Retrospective Studies | 13 | 2024 | 80674 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2002 | 460 | 0.040 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 1999 | 30 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2002 | 2293 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3253 | 0.040 |
Why?
|
Aspartic Acid | 1 | 2001 | 574 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2871 | 0.040 |
Why?
|
Urinary Bladder | 1 | 2005 | 1152 | 0.040 |
Why?
|
Immunochemistry | 1 | 2018 | 116 | 0.040 |
Why?
|
Septins | 1 | 2018 | 49 | 0.040 |
Why?
|
Sigmoid Neoplasms | 3 | 2004 | 53 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 17897 | 0.040 |
Why?
|
Astrocytoma | 1 | 1983 | 774 | 0.040 |
Why?
|
Syndrome | 2 | 2001 | 3271 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6392 | 0.040 |
Why?
|
Transplantation, Autologous | 3 | 1993 | 2112 | 0.040 |
Why?
|
Energy Intake | 2 | 2018 | 2133 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 856 | 0.040 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 15308 | 0.040 |
Why?
|
Deglutition Disorders | 1 | 2003 | 627 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2003 | 746 | 0.040 |
Why?
|
Odds Ratio | 4 | 2014 | 9652 | 0.040 |
Why?
|
Genital Neoplasms, Female | 3 | 2008 | 533 | 0.040 |
Why?
|
DNA | 4 | 2024 | 7189 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2000 | 435 | 0.040 |
Why?
|
Paclitaxel | 2 | 2002 | 1730 | 0.030 |
Why?
|
Genetics | 1 | 2017 | 114 | 0.030 |
Why?
|
Somatostatin | 1 | 1999 | 447 | 0.030 |
Why?
|
Adaptation, Psychological | 2 | 1998 | 2632 | 0.030 |
Why?
|
Amsacrine | 2 | 1987 | 19 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 1997 | 321 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2001 | 907 | 0.030 |
Why?
|
Genes, p16 | 1 | 2017 | 160 | 0.030 |
Why?
|
Diet Records | 1 | 2018 | 427 | 0.030 |
Why?
|
Semustine | 3 | 1994 | 11 | 0.030 |
Why?
|
Receptors, Retinoic Acid | 1 | 1997 | 224 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3245 | 0.030 |
Why?
|
Dietary Fiber | 1 | 2000 | 758 | 0.030 |
Why?
|
Regression Analysis | 2 | 2009 | 6345 | 0.030 |
Why?
|
Gastroesophageal Reflux | 1 | 2003 | 821 | 0.030 |
Why?
|
Morphine | 1 | 2000 | 656 | 0.030 |
Why?
|
Motor Activity | 1 | 2006 | 2712 | 0.030 |
Why?
|
Multivariate Analysis | 4 | 2013 | 12052 | 0.030 |
Why?
|
Antidotes | 1 | 1997 | 138 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2009 | 3594 | 0.030 |
Why?
|
DNA Nucleotidyltransferases | 2 | 1975 | 175 | 0.030 |
Why?
|
Drug Costs | 1 | 2004 | 1183 | 0.030 |
Why?
|
DNA Glycosylases | 1 | 2017 | 124 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2003 | 1316 | 0.030 |
Why?
|
Logistic Models | 3 | 2017 | 13249 | 0.030 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1997 | 534 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 5969 | 0.030 |
Why?
|
Clinical Competence | 3 | 2012 | 4788 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 12976 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 1997 | 361 | 0.030 |
Why?
|
Colectomy | 3 | 2007 | 686 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 1997 | 418 | 0.030 |
Why?
|
Patient Compliance | 1 | 2005 | 2688 | 0.030 |
Why?
|
Vaccination | 1 | 2007 | 3369 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6585 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 15920 | 0.030 |
Why?
|
Hemorrhage | 2 | 2006 | 3422 | 0.030 |
Why?
|
Young Adult | 7 | 2017 | 59221 | 0.030 |
Why?
|
Pain Measurement | 3 | 2012 | 3549 | 0.030 |
Why?
|
Penetrance | 1 | 2017 | 382 | 0.030 |
Why?
|
Thiazoles | 1 | 2002 | 1517 | 0.030 |
Why?
|
Nutritive Value | 1 | 2018 | 347 | 0.030 |
Why?
|
RNA-Directed DNA Polymerase | 2 | 1975 | 224 | 0.030 |
Why?
|
Cytogenetics | 1 | 1995 | 198 | 0.030 |
Why?
|
Decision Making | 3 | 2004 | 3931 | 0.030 |
Why?
|
Myelodysplastic Syndromes | 2 | 1996 | 1393 | 0.030 |
Why?
|
Preoperative Care | 1 | 2003 | 2241 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 1746 | 0.030 |
Why?
|
Research | 3 | 2008 | 1976 | 0.030 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1995 | 310 | 0.030 |
Why?
|
Microscopy, Immunoelectron | 1 | 2014 | 317 | 0.030 |
Why?
|
Physicians | 1 | 2012 | 4584 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2002 | 1052 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2000 | 1120 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2015 | 765 | 0.030 |
Why?
|
Tea | 1 | 2015 | 288 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1995 | 430 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 591 | 0.030 |
Why?
|
alpha-Fetoproteins | 1 | 1994 | 223 | 0.030 |
Why?
|
Leukocyte Count | 2 | 1995 | 1597 | 0.030 |
Why?
|
Obesity | 3 | 2008 | 12939 | 0.030 |
Why?
|
Lectins | 1 | 1975 | 489 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4567 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1995 | 606 | 0.030 |
Why?
|
Folic Acid | 1 | 2000 | 1323 | 0.030 |
Why?
|
Depression | 2 | 2012 | 8132 | 0.030 |
Why?
|
Phagosomes | 1 | 2014 | 199 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2013 | 6067 | 0.030 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 1993 | 98 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 754 | 0.030 |
Why?
|
Life Tables | 2 | 2004 | 364 | 0.030 |
Why?
|
Cyclophosphamide | 3 | 2005 | 2219 | 0.030 |
Why?
|
Genetic Testing | 1 | 2006 | 3537 | 0.030 |
Why?
|
Portal Vein | 1 | 1995 | 432 | 0.030 |
Why?
|
Databases, Factual | 3 | 2019 | 7966 | 0.030 |
Why?
|
Feces | 2 | 2018 | 1490 | 0.030 |
Why?
|
Pain | 2 | 2005 | 5072 | 0.030 |
Why?
|
Smoking | 2 | 2003 | 9055 | 0.030 |
Why?
|
Hierarchy, Social | 1 | 2012 | 24 | 0.030 |
Why?
|
Fibroblasts | 1 | 1983 | 4137 | 0.030 |
Why?
|
Platelet Count | 1 | 1995 | 782 | 0.030 |
Why?
|
Codes of Ethics | 1 | 2012 | 60 | 0.030 |
Why?
|
Vincristine | 4 | 1983 | 1036 | 0.030 |
Why?
|
Antioxidants | 1 | 2000 | 1667 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2013 | 543 | 0.020 |
Why?
|
Comorbidity | 2 | 2022 | 10516 | 0.020 |
Why?
|
Immunophenotyping | 3 | 1993 | 1867 | 0.020 |
Why?
|
Pancytopenia | 1 | 1993 | 102 | 0.020 |
Why?
|
Feasibility Studies | 3 | 2013 | 5250 | 0.020 |
Why?
|
Nuclear Proteins | 3 | 2017 | 5782 | 0.020 |
Why?
|
Meningeal Neoplasms | 2 | 1997 | 1246 | 0.020 |
Why?
|
Streptozocin | 2 | 2004 | 193 | 0.020 |
Why?
|
Heparin | 2 | 1990 | 1632 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1702 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1480 | 0.020 |
Why?
|
Signal Transduction | 1 | 2014 | 23416 | 0.020 |
Why?
|
Immunoblotting | 1 | 2014 | 1644 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2003 | 3571 | 0.020 |
Why?
|
Antigens, Surface | 3 | 1991 | 1607 | 0.020 |
Why?
|
Guideline Adherence | 2 | 2012 | 2220 | 0.020 |
Why?
|
Niacinamide | 1 | 2013 | 413 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2003 | 4027 | 0.020 |
Why?
|
Caffeine | 1 | 2015 | 701 | 0.020 |
Why?
|
Fructose | 1 | 2012 | 285 | 0.020 |
Why?
|
Digestive System | 3 | 1988 | 244 | 0.020 |
Why?
|
Drug Therapy, Combination | 8 | 1994 | 6304 | 0.020 |
Why?
|
Heat-Shock Proteins | 1 | 2014 | 795 | 0.020 |
Why?
|
Blast Crisis | 1 | 1990 | 102 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2011 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5493 | 0.020 |
Why?
|
Probability | 2 | 2009 | 2478 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 1992 | 233 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2000 | 2189 | 0.020 |
Why?
|
Chronic Disease | 1 | 2005 | 9319 | 0.020 |
Why?
|
Clinical Medicine | 1 | 1991 | 145 | 0.020 |
Why?
|
Germany | 1 | 2012 | 872 | 0.020 |
Why?
|
Up-Regulation | 1 | 2019 | 4111 | 0.020 |
Why?
|
Brain Neoplasms | 3 | 1983 | 9025 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 529 | 0.020 |
Why?
|
Genotype | 2 | 2015 | 12985 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1743 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2019 | 22174 | 0.020 |
Why?
|
Ubiquitin | 1 | 2014 | 839 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 899 | 0.020 |
Why?
|
Morals | 1 | 2012 | 289 | 0.020 |
Why?
|
Zinc | 1 | 2013 | 672 | 0.020 |
Why?
|
Laparoscopy | 1 | 2001 | 2035 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3584 | 0.020 |
Why?
|
Drug Resistance | 2 | 1985 | 1594 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 1991 | 312 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1993 | 677 | 0.020 |
Why?
|
Child | 14 | 2008 | 80152 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2003 | 3534 | 0.020 |
Why?
|
Head and Neck Neoplasms | 4 | 2007 | 2894 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2041 | 0.020 |
Why?
|
Personality | 1 | 2012 | 553 | 0.020 |
Why?
|
Catastrophization | 1 | 2012 | 349 | 0.020 |
Why?
|
Immunoproliferative Small Intestinal Disease | 1 | 1988 | 4 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4107 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1967 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 318 | 0.020 |
Why?
|
Gene Silencing | 2 | 2004 | 1495 | 0.020 |
Why?
|
Azirines | 1 | 1987 | 30 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3777 | 0.020 |
Why?
|
Dietary Carbohydrates | 1 | 2012 | 891 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 1 | 2008 | 228 | 0.020 |
Why?
|
Child, Preschool | 9 | 2001 | 42224 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1892 | 0.020 |
Why?
|
Methotrexate | 4 | 1991 | 1718 | 0.020 |
Why?
|
Survivors | 1 | 1998 | 2369 | 0.020 |
Why?
|
Arabinonucleotides | 1 | 1986 | 5 | 0.020 |
Why?
|
Vidarabine Phosphate | 1 | 1986 | 11 | 0.020 |
Why?
|
Calcium | 1 | 2000 | 5719 | 0.020 |
Why?
|
Neoplasm Invasiveness | 3 | 2004 | 3590 | 0.020 |
Why?
|
Blood Coagulation | 2 | 1990 | 1156 | 0.020 |
Why?
|
Quality Improvement | 2 | 2012 | 3808 | 0.020 |
Why?
|
Placenta | 2 | 1983 | 1711 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2013 | 782 | 0.020 |
Why?
|
Abnormalities, Drug-Induced | 1 | 1989 | 339 | 0.020 |
Why?
|
Mortality | 1 | 1997 | 2896 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1991 | 1624 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 1978 | 1923 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1540 | 0.020 |
Why?
|
Retreatment | 1 | 2007 | 598 | 0.020 |
Why?
|
Chromatography, DEAE-Cellulose | 2 | 1975 | 81 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 1985 | 135 | 0.020 |
Why?
|
Risk | 2 | 2010 | 9616 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 1985 | 398 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2006 | 270 | 0.020 |
Why?
|
Financing, Government | 1 | 2008 | 472 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1506 | 0.020 |
Why?
|
Transplantation, Homologous | 2 | 1991 | 4822 | 0.020 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2004 | 57 | 0.010 |
Why?
|
Rosaniline Dyes | 1 | 2004 | 50 | 0.010 |
Why?
|
Blood Coagulation Disorders | 1 | 1988 | 350 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2009 | 36415 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1993 | 3155 | 0.010 |
Why?
|
Antigens, CD | 1 | 1995 | 4009 | 0.010 |
Why?
|
Observation | 1 | 2006 | 310 | 0.010 |
Why?
|
Keratins | 1 | 2006 | 498 | 0.010 |
Why?
|
Hematologic Neoplasms | 2 | 2006 | 1895 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2000 | 3805 | 0.010 |
Why?
|
Decision Trees | 1 | 2006 | 505 | 0.010 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2004 | 93 | 0.010 |
Why?
|
Chromosomes, Human, 1-3 | 1 | 1983 | 21 | 0.010 |
Why?
|
Chromosomes, Human, 6-12 and X | 1 | 1983 | 69 | 0.010 |
Why?
|
Life Style | 1 | 2015 | 3907 | 0.010 |
Why?
|
Immunologic Factors | 1 | 1993 | 1589 | 0.010 |
Why?
|
Prednisolone | 2 | 1983 | 324 | 0.010 |
Why?
|
Terminally Ill | 1 | 2005 | 240 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20119 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.010 |
Why?
|
Sensitivity and Specificity | 3 | 2004 | 14675 | 0.010 |
Why?
|
Stromal Cells | 1 | 2009 | 1329 | 0.010 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2004 | 277 | 0.010 |
Why?
|
Severity of Illness Index | 3 | 2009 | 15841 | 0.010 |
Why?
|
Models, Molecular | 1 | 2013 | 5406 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8300 | 0.010 |
Why?
|
Octreotide | 1 | 2004 | 154 | 0.010 |
Why?
|
Tachycardia | 1 | 1985 | 599 | 0.010 |
Why?
|
Fever | 2 | 1988 | 1618 | 0.010 |
Why?
|
Lomustine | 1 | 2002 | 60 | 0.010 |
Why?
|
Leadership | 1 | 2012 | 1385 | 0.010 |
Why?
|
Intestinal Polyps | 1 | 1983 | 105 | 0.010 |
Why?
|
Medical Records | 2 | 2004 | 1409 | 0.010 |
Why?
|
Bacterial Infections | 1 | 1991 | 1390 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1983 | 351 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3239 | 0.010 |
Why?
|
Drug Implants | 1 | 1983 | 230 | 0.010 |
Why?
|
Anorexia | 1 | 1983 | 152 | 0.010 |
Why?
|
Random Allocation | 2 | 1989 | 2393 | 0.010 |
Why?
|
Procarbazine | 1 | 1982 | 172 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1982 | 129 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2009 | 1301 | 0.010 |
Why?
|
Medical History Taking | 1 | 2006 | 773 | 0.010 |
Why?
|
Liver | 4 | 2014 | 7514 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2006 | 1057 | 0.010 |
Why?
|
Coloring Agents | 1 | 2004 | 561 | 0.010 |
Why?
|
Recombinant Proteins | 3 | 2001 | 6504 | 0.010 |
Why?
|
Exanthema | 1 | 2006 | 503 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2014 | 9520 | 0.010 |
Why?
|
Dihydrouracil Dehydrogenase (NAD+) | 1 | 2001 | 1 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 1992 | 1663 | 0.010 |
Why?
|
Hypotension | 2 | 1985 | 879 | 0.010 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2004 | 355 | 0.010 |
Why?
|
Radiotherapy | 2 | 1991 | 1499 | 0.010 |
Why?
|
Mitoguazone | 1 | 1981 | 11 | 0.010 |
Why?
|
Thymidylate Synthase | 1 | 2001 | 74 | 0.010 |
Why?
|
Breast Neoplasms | 8 | 2008 | 20982 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1593 | 0.010 |
Why?
|
Maternal-Fetal Exchange | 1 | 1983 | 461 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9297 | 0.010 |
Why?
|
Burkitt Lymphoma | 1 | 1983 | 335 | 0.010 |
Why?
|
Bleomycin | 1 | 1982 | 495 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2004 | 1577 | 0.010 |
Why?
|
Vinblastine | 1 | 1982 | 488 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 1983 | 478 | 0.010 |
Why?
|
North Carolina | 1 | 2001 | 324 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3691 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 2002 | 442 | 0.010 |
Why?
|
Glaucarubin | 1 | 1979 | 3 | 0.010 |
Why?
|
Phenotype | 4 | 2006 | 16575 | 0.010 |
Why?
|
North America | 1 | 2004 | 1284 | 0.010 |
Why?
|
Antigens, Neoplasm | 2 | 1986 | 1985 | 0.010 |
Why?
|
Nausea | 1 | 1983 | 678 | 0.010 |
Why?
|
Guanidines | 1 | 1981 | 194 | 0.010 |
Why?
|
Socioeconomic Factors | 2 | 1998 | 7804 | 0.010 |
Why?
|
Rectum | 1 | 2004 | 891 | 0.010 |
Why?
|
Pyrans | 1 | 1979 | 49 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2006 | 5300 | 0.010 |
Why?
|
DNA Primers | 1 | 2004 | 2814 | 0.010 |
Why?
|
Intestinal Absorption | 1 | 1980 | 400 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1988 | 2196 | 0.010 |
Why?
|
Dacarbazine | 1 | 1982 | 559 | 0.010 |
Why?
|
Esophagoscopy | 1 | 2001 | 398 | 0.010 |
Why?
|
Body Composition | 1 | 2008 | 2427 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2014 | 14392 | 0.010 |
Why?
|
Oxidoreductases | 1 | 2001 | 411 | 0.010 |
Why?
|
Myeloma Proteins | 1 | 1978 | 71 | 0.010 |
Why?
|
Nitrosourea Compounds | 1 | 1977 | 32 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1111 | 0.010 |
Why?
|
Cystadenocarcinoma | 1 | 1978 | 54 | 0.010 |
Why?
|
Cystadenoma | 1 | 1978 | 79 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2000 | 11101 | 0.010 |
Why?
|
Microsomes | 2 | 1975 | 251 | 0.010 |
Why?
|
Sarcoma | 1 | 2008 | 1800 | 0.010 |
Why?
|
Brain Diseases | 1 | 1986 | 1545 | 0.010 |
Why?
|
Genetic Markers | 1 | 2004 | 2599 | 0.010 |
Why?
|
Maytansine | 1 | 1978 | 86 | 0.010 |
Why?
|
Prednisone | 1 | 1982 | 1565 | 0.010 |
Why?
|
Anxiety | 1 | 2012 | 4569 | 0.010 |
Why?
|
Overweight | 1 | 2008 | 2418 | 0.010 |
Why?
|
Naphthol AS D Esterase | 2 | 1989 | 14 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2004 | 6124 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2009 | 3671 | 0.010 |
Why?
|
Colonic Polyps | 1 | 2002 | 552 | 0.010 |
Why?
|
Colon | 1 | 2004 | 1791 | 0.010 |
Why?
|
Antigen-Antibody Complex | 1 | 1978 | 509 | 0.010 |
Why?
|
Ureteral Obstruction | 1 | 1978 | 293 | 0.010 |
Why?
|
Melphalan | 1 | 1977 | 420 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2002 | 2359 | 0.010 |
Why?
|
Ethylmaleimide | 1 | 1975 | 69 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2001 | 1624 | 0.010 |
Why?
|
Body Weight | 2 | 2003 | 4618 | 0.010 |
Why?
|
Oxazines | 1 | 1978 | 349 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2009 | 26071 | 0.010 |
Why?
|
Zinc Fingers | 1 | 1997 | 575 | 0.010 |
Why?
|
Hypercalcemia | 1 | 1978 | 423 | 0.010 |
Why?
|
Oncogenic Viruses | 1 | 1975 | 37 | 0.010 |
Why?
|
Retroviridae | 2 | 1975 | 850 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1975 | 452 | 0.010 |
Why?
|
Pedigree | 1 | 1983 | 4537 | 0.010 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 1997 | 305 | 0.010 |
Why?
|
B-Lymphocytes | 2 | 1986 | 4744 | 0.010 |
Why?
|
Base Sequence | 2 | 2004 | 12404 | 0.010 |
Why?
|
Chromatography, Ion Exchange | 1 | 1974 | 294 | 0.010 |
Why?
|
Pyrimidines | 1 | 2006 | 3027 | 0.010 |
Why?
|
Cell Fractionation | 1 | 1974 | 248 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 1987 | 2571 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1974 | 2561 | 0.010 |
Why?
|
Haplorhini | 1 | 1974 | 523 | 0.010 |
Why?
|
RNA Viruses | 1 | 1975 | 110 | 0.010 |
Why?
|
Embryonic and Fetal Development | 1 | 1974 | 420 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1978 | 1989 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1980 | 801 | 0.010 |
Why?
|
Lymphocyte Activation | 2 | 1993 | 5478 | 0.010 |
Why?
|
HIV Infections | 1 | 2000 | 17347 | 0.010 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 1997 | 682 | 0.010 |
Why?
|
Peroxidase | 2 | 1989 | 610 | 0.010 |
Why?
|
Macaca | 1 | 1974 | 410 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2006 | 3788 | 0.010 |
Why?
|
Alleles | 1 | 2004 | 6857 | 0.010 |
Why?
|
Bone Marrow Examination | 1 | 1993 | 155 | 0.010 |
Why?
|
Cerebellar Neoplasms | 1 | 1978 | 586 | 0.010 |
Why?
|
Disseminated Intravascular Coagulation | 2 | 1987 | 187 | 0.010 |
Why?
|
Radiography | 1 | 2004 | 6974 | 0.010 |
Why?
|
Papio | 1 | 1974 | 669 | 0.010 |
Why?
|
Cross Reactions | 1 | 1974 | 819 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2006 | 11067 | 0.010 |
Why?
|
Uric Acid | 1 | 1978 | 807 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 14025 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 1998 | 3418 | 0.010 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 1991 | 111 | 0.010 |
Why?
|
Adenoma | 1 | 2002 | 2159 | 0.010 |
Why?
|
Nervous System Neoplasms | 1 | 1991 | 91 | 0.010 |
Why?
|
Histocompatibility Antigens Class II | 2 | 1986 | 1435 | 0.010 |
Why?
|
Laparotomy | 1 | 1993 | 456 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1978 | 1191 | 0.010 |
Why?
|
Aspartate Aminotransferases | 1 | 1992 | 411 | 0.010 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 114 | 0.010 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 317 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2004 | 4935 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 3702 | 0.010 |
Why?
|
Injections, Spinal | 1 | 1991 | 317 | 0.010 |
Why?
|
Biological Availability | 1 | 1991 | 389 | 0.010 |
Why?
|
Species Specificity | 1 | 1974 | 2406 | 0.010 |
Why?
|
S Phase | 1 | 1991 | 423 | 0.010 |
Why?
|
Pancreaticoduodenectomy | 1 | 1993 | 509 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1991 | 1545 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1988 | 5321 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1989 | 26199 | 0.010 |
Why?
|
Skin | 1 | 1983 | 4473 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 1992 | 859 | 0.010 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 897 | 0.000 |
Why?
|
Pancreatectomy | 1 | 1993 | 811 | 0.000 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1991 | 646 | 0.000 |
Why?
|
Sigmoidoscopy | 1 | 1988 | 151 | 0.000 |
Why?
|
Anti-Bacterial Agents | 3 | 1988 | 7407 | 0.000 |
Why?
|
Antigens, CD19 | 1 | 1991 | 424 | 0.000 |
Why?
|
Epitopes | 1 | 1974 | 2504 | 0.000 |
Why?
|
Histocytochemistry | 1 | 1989 | 697 | 0.000 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 890 | 0.000 |
Why?
|
Infant | 4 | 1983 | 36169 | 0.000 |
Why?
|
Sulfamethoxazole | 1 | 1987 | 51 | 0.000 |
Why?
|
Remission, Spontaneous | 2 | 1978 | 384 | 0.000 |
Why?
|
Trimethoprim | 1 | 1987 | 78 | 0.000 |
Why?
|
Fiber Optic Technology | 1 | 1988 | 290 | 0.000 |
Why?
|
Creatinine | 1 | 1992 | 1897 | 0.000 |
Why?
|
Kidney | 2 | 1980 | 7033 | 0.000 |
Why?
|
Gene Rearrangement | 1 | 1991 | 1125 | 0.000 |
Why?
|
Gestational Age | 1 | 1974 | 3580 | 0.000 |
Why?
|
Animals | 2 | 2014 | 168079 | 0.000 |
Why?
|
Clinical Protocols | 1 | 1991 | 1436 | 0.000 |
Why?
|
Drug Interactions | 1 | 1989 | 1417 | 0.000 |
Why?
|
Receptors, Immunologic | 1 | 1991 | 1408 | 0.000 |
Why?
|
Acidosis | 1 | 1986 | 269 | 0.000 |
Why?
|
Radiation Dosage | 1 | 1993 | 1962 | 0.000 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2002 | 5666 | 0.000 |
Why?
|
Demyelinating Diseases | 1 | 1986 | 352 | 0.000 |
Why?
|
Kidney Neoplasms | 1 | 1981 | 4251 | 0.000 |
Why?
|
Autopsy | 1 | 1987 | 1010 | 0.000 |
Why?
|
Neprilysin | 1 | 1986 | 478 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3803 | 0.000 |
Why?
|
Hepatomegaly | 1 | 1982 | 84 | 0.000 |
Why?
|
Coma | 1 | 1986 | 484 | 0.000 |
Why?
|
Blindness | 1 | 1986 | 585 | 0.000 |
Why?
|
Stress, Psychological | 1 | 1998 | 4487 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1990 | 1201 | 0.000 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 2549 | 0.000 |
Why?
|
Registries | 1 | 1998 | 8247 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1993 | 4340 | 0.000 |
Why?
|
Fetal Death | 1 | 1983 | 435 | 0.000 |
Why?
|
Immunoglobulins | 1 | 1984 | 850 | 0.000 |
Why?
|
Povidone | 1 | 1980 | 30 | 0.000 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1987 | 943 | 0.000 |
Why?
|
Flow Cytometry | 1 | 1991 | 5871 | 0.000 |
Why?
|
Tobramycin | 1 | 1980 | 65 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1974 | 7571 | 0.000 |
Why?
|
Myocardium | 1 | 1973 | 4746 | 0.000 |
Why?
|
Genes | 1 | 1984 | 1820 | 0.000 |
Why?
|
Heart | 1 | 1973 | 4431 | 0.000 |
Why?
|
Dysgerminoma | 1 | 1980 | 66 | 0.000 |
Why?
|
Quassins | 1 | 1979 | 6 | 0.000 |
Why?
|
Multiple Myeloma | 1 | 1978 | 5145 | 0.000 |
Why?
|
Fluorescent Antibody Technique | 1 | 1984 | 2468 | 0.000 |
Why?
|
Palpation | 1 | 1980 | 166 | 0.000 |
Why?
|
Methylprednisolone | 1 | 1980 | 386 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1981 | 1703 | 0.000 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 1978 | 317 | 0.000 |
Why?
|
Pilot Projects | 1 | 1991 | 8642 | 0.000 |
Why?
|
Staining and Labeling | 1 | 1981 | 1080 | 0.000 |
Why?
|
Fetus | 1 | 1984 | 1864 | 0.000 |
Why?
|
Teratoma | 1 | 1980 | 404 | 0.000 |
Why?
|
Fetal Blood | 1 | 1983 | 1348 | 0.000 |
Why?
|
Bone Neoplasms | 2 | 1980 | 2527 | 0.000 |
Why?
|
Cell Differentiation | 2 | 1984 | 11509 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1991 | 12747 | 0.000 |
Why?
|
Bone Marrow Cells | 1 | 1983 | 2410 | 0.000 |
Why?
|
Inclusion Bodies, Viral | 1 | 1975 | 45 | 0.000 |
Why?
|
Nervous System | 1 | 1978 | 545 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1980 | 1303 | 0.000 |
Why?
|
Intestinal Diseases | 1 | 1978 | 503 | 0.000 |
Why?
|
Health Education | 1 | 1980 | 1049 | 0.000 |
Why?
|
Diagnostic Errors | 1 | 1978 | 1265 | 0.000 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 926 | 0.000 |
Why?
|
Cardiomegaly | 1 | 1973 | 590 | 0.000 |
Why?
|
Cytoplasm | 1 | 1975 | 1498 | 0.000 |
Why?
|
Heart Failure | 1 | 1973 | 11701 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1986 | 10203 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1991 | 15637 | 0.000 |
Why?
|
DNA, Viral | 1 | 1975 | 2195 | 0.000 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1979 | 2019 | 0.000 |
Why?
|
RNA, Viral | 1 | 1975 | 2839 | 0.000 |
Why?
|
Chromatin | 1 | 1973 | 2946 | 0.000 |
Why?
|